ArticleJournal of the advanced practitioner in oncology2026
Optimizing Polycythemia Vera Management Through a Collaborative Care Model Between Leukemia Oncologists and an Integrated Specialty Pharmacy.
Article in Journal of the advanced practitioner in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that requires long-term hematologic control and symptom monitoring. Despite advanced therapies and treatment guidelines, real-world adherence to therapeutic goals and routine symptom assessment remains inconsistent, particularly outside the academic setting. To optimize care, a pharmacist-led clinical support program was implemented at Levine Cancer Institute, a large regional hematologic malignancy center, in collaboration with the integrated institutional Atrium Health Specialty Pharmacy Service (SPS). This program aimed to standardize PV care system-wide by improving hematocrit (Hct) control and supporting symptom burden assessment via Myeloproliferative Neoplasm Symptom Assessment Form (MPN-10) scores. Through diagnosis code screening and identification of patients with Hct ≥ 45%, the SPS pharmacist team provided clinical reviews, pharmacotherapy recommendations, financial access support, and coordinated care, including dispensing medication and providing medication education. Interim analysis demonstrated improved identification of opportunities for optimization, with sustained provider engagement. This model highlights the opportunity for advanced practitioners, including pharmacists, to improve disease control and quality of life for patients with PV.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.